1222 related articles for article (PubMed ID: 27920219)
1. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
2. The proprotein convertases are potential targets in the treatment of dyslipidemia.
Seidah NG; Prat A
J Mol Med (Berl); 2007 Jul; 85(7):685-96. PubMed ID: 17351764
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
4. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
Norata GD; Tavori H; Pirillo A; Fazio S; Catapano AL
Cardiovasc Res; 2016 Oct; 112(1):429-42. PubMed ID: 27496869
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
[TBL] [Abstract][Full Text] [Related]
6. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
8. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
10. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
11. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 and Hypercholesterolemia: Therapeutic Approach.
Obradovic M; Zaric B; Sudar-Milovanovic E; Ilincic B; Stokic E; Perovic M; Isenovic ER
Curr Drug Targets; 2018; 19(9):1058-1067. PubMed ID: 29210646
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
[No Abstract] [Full Text] [Related]
15. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
16. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions.
Seidah NG; Sadr MS; Chrétien M; Mbikay M
J Biol Chem; 2013 Jul; 288(30):21473-81. PubMed ID: 23775089
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 antibodies: A new class of lipid-lowering drugs.
Gouni-Berthold I
Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
[TBL] [Abstract][Full Text] [Related]
18. Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
Guo Y; Yan B; Gui Y; Tang Z; Tai S; Zhou S; Zheng XL
J Cell Physiol; 2021 Apr; 236(4):2333-2351. PubMed ID: 32875580
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 inhibition in patients with hypercholesterolemia.
Desai NR; Sabatine MS
Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
